Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StockNewsNow.com Publishes New SNNLive Video Interview with RXi Pharmaceuticals Corporation

LOS ANGELES, CA--(Marketwired - October 27, 2015) - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Dr. Geert Cauwenbergh, President & CEO of RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing therapeutics, primarily in the areas of dermatology and ophthalmology, according to the Company's website (see here: www.rxipharma.com). The video interview was recorded on Thursday, October 15th, 2015 at the Dawson James Small Cap Growth Conference 2015 in Jupiter, FL.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

RXi Pharmaceuticals - Discovering and Developing Therapeutics Based on its Self-Delivering RNAi (sd-rxRNA®) Platform and Immunotherapy Agents

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS.

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, addressing high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and retinal scarring. It also includes an immunomodulator, Samcyprone™, a proprietary topical formulation of diphenylcyclopropenone (DPCP), for the treatment of such disorders as alopecia areata, warts, and cutaneous metastases of melanoma. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.

Company description and for more information: www.rxipharma.com

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature user-generated video, SNN-produced video like SNNLive CEO video interviews, as well as research reports, radio interviews, PowerPoint presentations, articles, and their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for -- all here on StockNewsNow.com.

Embedded Video Available: https://www.youtube.com/watch?v=5iz8YmI8y2Y

StockNewsNow.com
Email contact



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today